HSS Study Finds CAR T-Cell Therapy Reduces Disease Activity in Hard-to-Treat Lupus

• HSS - Hospital for Special Surgery presented findings supporting CAR T-cell therapy for difficult-to-treat lupus at ACR Convergence 2026.
• The pooled analysis covered 31 studies involving 243 patients who had previously tried at least two immunosuppressants, evaluating outcomes over two years.
• Treatment led to near-complete symptom resolution by six months in patients with initially high disease activity.
• Inflammatory reactions were generally mild; neurological complications were infrequent.
• Larger prospective studies are needed to assess long-term outcomes and identify patients most likely to benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HSS - Hospital for Special Surgery published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.